Commercial code

Voting Rights and Shares Capital of the Company

Retrieved on: 
Tuesday, June 11, 2024

PARIS, June 11, 2024 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com

Key Points: 

According to the article L.233-8 II of the French Commercial Code, Nanobiotix will make a new monthly publication of the total number of voting rights and shares comprising Nanobiotix’s capital if those figures differ from the information previously disclosed.

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

Retrieved on: 
Wednesday, June 5, 2024

Any shareholder wishing to receive, by mail or e-mail, Meeting documents referred to in Article R. 22-10-23 of the French Commercial Code, may make a request until the fifth day inclusive before the Meeting date, by contacting the Company at [email protected] .

Key Points: 
  • Any shareholder wishing to receive, by mail or e-mail, Meeting documents referred to in Article R. 22-10-23 of the French Commercial Code, may make a request until the fifth day inclusive before the Meeting date, by contacting the Company at [email protected] .
  • Shareholders may also access the Meeting documentation at the Company’s registered office.
  • Prior to joining Valneva in 2020, Ms. Wergin practiced in the corporate group of a major international law firm and the in-house legal team of a Fortune 500 company.
  • We are delighted to be able to elevate one of our own to this position.”

EQS-News: Daldrup & Söhne AG increases EBIT by 42.6 % in 2023

Retrieved on: 
Tuesday, June 4, 2024

Euro, EBIT margin between 5 % and 7 %

Key Points: 
  • Euro, EBIT margin between 5 % and 7 %
    Oberhaching / Ascheberg, June 3, 2024 - The drilling technology and geothermal specialist Daldrup & Söhne AG (ISIN DE0007830572) achieved consolidated earnings before interest and taxes (EBIT) of EUR 2.6 million (previous year: EUR 1.8 million) in the 2023 financial year (January 1 - December 31), calculated in accordance with the German Commercial Code (HGB).
  • The aforementioned key figures document the pleasing development of Daldrup & Söhne AG in 2023.
  • The business model of Daldrup & Söhne AG is largely independent of economic cycles and is characterized by a long-term order environment for the provision of public services.
  • Daldrup is well positioned in the market and is a sought-after source of expertise and valued drilling service provider.

Median Technologies Announces the Availability of the Preparatory Documents for the Shareholders’ Ordinary and Extraordinary General Meeting on June 19, 2024

Retrieved on: 
Monday, June 3, 2024

All useful information relating to this Shareholders’ General Meeting is regularly updated on Median Technologies’ website.

Key Points: 
  • All useful information relating to this Shareholders’ General Meeting is regularly updated on Median Technologies’ website.
  • Shareholders may exercise their voting rights before the holding of the Shareholders’ General Meeting, either by returning their postal voting form, or by giving proxy.
  • The detailed procedures relating to the exercise of the right to vote are specified in the notice of the Shareholders’ General Meeting, available here on Median’s website.
  • The preliminary notice of the Shareholders’ General Meeting has been published in the BALO (Bulletin des annonces légales obligatoires) on May 13, 2024, and has not been subject to any modification.

Combined General Meeting of June 20, 2024 - Availability of the preparatory documents

Retrieved on: 
Thursday, May 30, 2024

Shareholders are invited to participate in the Combined General Meeting that will be held on June 20, 2024 at 9 a.m. at Hôtel Castel Burgond, 3 route de Troyes, 21121 Daix (France).

Key Points: 
  • Shareholders are invited to participate in the Combined General Meeting that will be held on June 20, 2024 at 9 a.m. at Hôtel Castel Burgond, 3 route de Troyes, 21121 Daix (France).
  • The preliminary notice of meeting comprising the agenda and the draft resolutions, as well as information on how to attend and vote at the Combined General Meeting, was published in the Bulletin des Annonces Légales Obligatoires (BALO) n°58 of May 13, 2024 and a translation was filed with the Securities and Exchange Commission on May 13, 2024.
  • Documents listed in Article R.22-10-23 of the French Commercial Code are available on Inventiva’s website mentioned above as of tomorrow, the twenty-first day that precedes the General Meeting.
  • In accordance with applicable regulatory provisions:
    any shareholder holding registered shares may, up to the fifth day, including, prior to the General Meeting, request these documents to be sent by the Company.

Voting Rights and Shares Capital of the Company

Retrieved on: 
Thursday, May 16, 2024

PARIS, May 16, 2024 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com

Key Points: 

According to the article L.233-8 II of the French Commercial Code, Nanobiotix will make a new monthly publication of the total number of voting rights and shares comprising Nanobiotix’s capital if those figures differ from the information previously disclosed.

AB Science reports its revenues for the year 2023 and provides an update on its activities

Retrieved on: 
Wednesday, May 15, 2024

As a result of the focus strategy, AB Science has decided to adapt its organization, which lead to a significant reduction in costs.

Key Points: 
  • As a result of the focus strategy, AB Science has decided to adapt its organization, which lead to a significant reduction in costs.
  • the volume-weighted average price of AB Science shares on Euronext Paris over the three trading sessions preceding the drawdown request).
  • Alpha Blue Ocean is now responsible for the orderly sale of the AB Science shares subscribed for.
  • AB Science confirms its eligibility for PEA-PME (a share savings plan aimed at providing finance to SMEs) in accordance with decree no.

EQS-News: Mountain Alliance AG publishes Annual Report 2023 – Net Asset Value per share at € 6.64

Retrieved on: 
Friday, May 10, 2024

Net Asset Value (NAV) at € 45.7 million (December 31, 2022: € 47.4 million)

Key Points: 
  • Net Asset Value (NAV) at € 45.7 million (December 31, 2022: € 47.4 million)
    NAV per share at € 6.64 (December 31, 2022: € 6.89)
    Munich, May 7, 2024 – Mountain Alliance AG (MA, ISIN DE000A12UK08) today publishes its annual report 2023 and its Net Asset Value (NAV) as at December 31, 2023.
  • The annual report of Mountain Alliance AG has been prepared in accordance with the German Commercial Code (HGB) and the German Stock Corporation Act (AktG).
  • Considering net financial liabilities of € 1.8 million, the net asset value (NAV) of Mountain Alliance AG amounted to € 45.7 million after € 47.4 million at the end of 2022.
  • Calculation of MA Group´s Net Asset Value as at December 31, 2023

Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents

Retrieved on: 
Friday, May 10, 2024

Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents

Key Points: 
  • Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • The preliminary notice of meeting comprising the agenda and the draft resolutions, as well asinformation on how to attend and vote at the General Meeting, was published in the Bulletin des Annonces Légales Obligatoires (BALO) of April 24, 2024 (N°2400962).
  • The information and preparatory documents for this General Meeting are made available to the Company’s shareholders in accordance with the procedures and within the time limits provided for by the applicable legal and regulatory provisions.

Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents

Retrieved on: 
Tuesday, May 7, 2024

Abivax annual ordinary and extraordinary general meeting of May 30, 2024

Key Points: 
  • Abivax annual ordinary and extraordinary general meeting of May 30, 2024
    PARIS, France, May 7, 2024, 10:00PM CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, informs its shareholders that its ordinary and extraordinary general meeting (the “General Meeting”) will be held on May 30, 2024, at 10:00 am (CEST), at the offices of Dechert (Paris) LLP, located at 22 rue Bayard in Paris (75008), France.
  • The preliminary notice of meeting comprising the agenda and the draft resolutions, as well asinformation on how to attend and vote at the General Meeting, was published in the Bulletin des Annonces Légales Obligatoires (BALO) of April 24, 2024 (N°2400962).
  • The information and preparatory documents for this General Meeting are made available to the Company’s shareholders in accordance with the procedures and within the time limits provided for by the applicable legal and regulatory provisions.
  • The documents referred to in Article R.22-10-23 of the French Commercial Code are available on the Company’s website: www.abivax.com
    Any shareholder wishing to receive these documents by post or electronically may make a request until midnight, Paris time, on May 25, 2024 (i.e., the fifth day before the General Meeting) by contacting the Company.